Key result
Losartan 50 mg significantly reduced mean post-dialysis systolic blood pressure by 2.4 mmHg over 8 weeks in euvolemic hypertensive patients, whereas standard therapy showed a non-significant 0.3 mmHg reduction.
Why the study?
Does losartan 50 mg reduce post-dialysis blood pressure in euvolemic hypertensive patients on hemodialysis?
RCT (n=88)
Single-blind
Covariate-adaptive randomization
Yes
Does losartan 50 mg reduce post-dialysis blood pressure in euvolemic hypertensive patients on hemodialysis?
Absolute Event Rate: 2.4% vs 0.3%
p-value: p=<0.001
Losartan 50 mg provided a slow, steady, and significant decline in post-dialysis systolic blood pressure among euvolemic hypertensive hemodialysis patients compared to standard non-RAAS therapy.
Losartan 50 mg may aid post-dialysis SBP control in euvolemic hypertensive HD patients; extends RCT evidence for low-dose ARB versus non-RAAS therapy.
To assess the effectiveness of losartan 50 mg on post dialysis euvolemic hypertensive patients against standard antihypertensive pharmacotherapy. A multicentre, prospective, randomized, single-blind trial was conducted to assess the effect of losartan 50 mg every other day (EOD), once a morning (OM) among post-dialysis euvolemic hypertensive patients. Covariate-adaptive randomization was used to allocate participants to a standard or treatment arm, and they were followed up for eight weeks. Pre-, intra- and post-dialysis session blood pressure (BP) measurements were recorded along with any adverse events. A total of 88 patients were randomized into standard (n = 44) and treatment arms (n = 44) and were followed for a period of 8 weeks. In the standard group, the mean post-dialysis blood pressure dropped by 0.3 mmHg by the end of the 8 th week. However the treatment arm reported a drop of 2.4 mmHg of BP drop during the 8-week trial period. Analysis suggests that there was a significant difference in blood pressure readings at the end of 8 weeks among patients treated with losartan (P < 0.001). However, no such statistical association was observed in the standard arm (P 0.75). A slow, steady significant decline in post-dialysis BP was observed among euvolemic hypertensive patients that were treated with losartan 50 mg.
No takes yet. Share an insight, caveat, or question.
Aftab et al. (2016) conducted an RCT in Post-dialysis euvolemic hypertension (n=88). Losartan vs. Standard antihypertensive pharmacotherapy (excluding RAAS inhibitors) was evaluated on Reduction in mean post-dialysis systolic blood pressure at 8 weeks (p=<0.001). Losartan 50 mg significantly reduced mean post-dialysis systolic blood pressure by 2.4 mmHg over 8 weeks in euvolemic hypertensive patients, whereas standard therapy showed a non-significant 0.3 mmHg reduction.